According to the multivariate analysis, AJCC stage III/IV disease and mutations in FGF3, TP63, FGF19, and FAT1 were associated with significantly increased hazard ratios among patients with ESCC (Table 1,  ∗p < 0.05). Here, FAT1 is linked to esophageal squamous cell carcinoma.